These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37084155)

  • 1. Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.
    Xu C; Wang Y; Hong Y; Yao R; Wu L; Shen X; Qu Y; Zhang Z; Zhu W; Yang Y; Chen W; Zhou Y; Liang Z
    Breast Cancer Res Treat; 2023 Jun; 199(3):603-615. PubMed ID: 37084155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
    Castagnoli L; Iorio E; Dugo M; Koschorke A; Faraci S; Canese R; Casalini P; Nanni P; Vernieri C; Di Nicola M; Morelli D; Tagliabue E; Pupa SM
    J Cell Physiol; 2019 Feb; 234(2):1768-1779. PubMed ID: 30132876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
    Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M
    Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.
    Vassilakopoulou M; Togun T; Dafni U; Cheng H; Bordeaux J; Neumeister VM; Bobos M; Pentheroudakis G; Skarlos DV; Pectasides D; Kotoula V; Fountzilas G; Rimm DL; Psyrri A
    PLoS One; 2014; 9(6):e99131. PubMed ID: 24968015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels.
    Sorokin M; Ignatev K; Barbara V; Vladimirova U; Muraveva A; Suntsova M; Gaifullin N; Vorotnikov I; Kamashev D; Bondarenko A; Baranova M; Poddubskaya E; Buzdin A
    Biochemistry (Mosc); 2020 Jul; 85(7):758-772. PubMed ID: 33040720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of p95HER2 in trastuzumab resistance in breast cancer.
    Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
    J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
    Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
    Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
    [No Abstract]   [Full Text] [Related]  

  • 10. Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab.
    Singla H; Kaur RP; Shafi G; Vashistha R; Banipal RPS; Kumar V; Munshi A
    Mol Biol Rep; 2019 Feb; 46(1):823-831. PubMed ID: 30535550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
    Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
    J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
    Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M
    Mol Oncol; 2014 Feb; 8(1):20-6. PubMed ID: 24075779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
    Pizzamiglio S; Cosentino G; Ciniselli CM; De Cecco L; Cataldo A; Plantamura I; Triulzi T; El-Abed S; Wang Y; Bajji M; Nuciforo P; Huober J; Ellard SL; Rimm DL; Gombos A; Daidone MG; Verderio P; Tagliabue E; Di Cosimo S; Iorio MV
    Cancer Med; 2022 Jan; 11(2):332-339. PubMed ID: 34921525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
    Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
    Triulzi T; De Cecco L; Sandri M; Prat A; Giussani M; Paolini B; Carcangiu ML; Canevari S; Bottini A; Balsari A; Menard S; Generali D; Campiglio M; Di Cosimo S; Tagliabue E
    Oncotarget; 2015 Sep; 6(29):28173-82. PubMed ID: 26334217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer: A pilot study.
    Wang J; Xu R; Yuan H; Zhang Y; Cheng S
    Medicine (Baltimore); 2019 Jun; 98(26):e15872. PubMed ID: 31261495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
    Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
    Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial.
    Miles D; Im YH; Fung A; Yoo B; Knott A; Heeson S; Beattie MS; Swain SM
    Ann Oncol; 2017 Nov; 28(11):2761-2767. PubMed ID: 29112701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.